4 results about "Existing Treatment" patented technology

The invention relates to a biomarker combination for treating SHH subtype medulloblastoma, and aims to solve the problems that existing treatment targets are deficient, the curative effect is limited and precise treatment is insufficient. The invention reveals that an m6A-YTHDF2 signal axis is a novel treatment target of SHH-MB for the first time, the YTHDF2 regulates and controls the expression of a downstream target gene DENND2A through an m6A dependency mode, the high expression of the YTHDF2 is related to poor prognosis of a patient, and knock-down of the YTHDF2 can significantly inhibit the proliferation and balling ability of SHH-MB cells. According to the invention, the TET-ON regulated SHH-MB cell line capable of inducing to knock down YTHDF2 is constructed, and a tool is provided for drug screening; it is clear that a YTHDF2 inhibitor (such as DC-Y13-27 and the like) can achieve the anti-tumor effect by down-regulating DENND2A expression, and the drug sensitivity of SHH-MB tumor cells to a Hedgehog signal channel small molecule inhibitor Vismodegib (GDC-0449) is improved.

This invention discloses an injectable hydrogel loaded with 4-octyl itaconic acid, its preparation method, and its applications, belonging to the field of biomedical materials technology. The injectable hydrogel is formed by enzymatic cross-linking of a hyaluronic acid-tyramine complex to create a three-dimensional network, with 4-octyl itaconic acid encapsulated within this network structure. This invention allows for precise implantation of the hydrogel into the intervertebral disc lesion via minimally invasive injection, achieving local high-concentration drug accumulation. The three-dimensional network of the hydrogel serves as a drug reservoir, enabling continuous and controllable release of 4-OI, prolonging the drug's duration of action and achieving long-term therapeutic effects. Simultaneously, the loaded 4-OI specifically activates the Nrf2 / GPX4 antioxidant pathway in nucleus pulposus cells, mechanistically antagonizing ferroptosis and matrix degradation, thus achieving a dual function of mechanical support and biological therapy. It exhibits good biocompatibility and solves the problems of difficult targeted drug delivery, short-lived efficacy, and lack of disease-modifying effects in existing treatments for intervertebral disc degeneration.

The utility model discloses a treatment head and therapeutic instrument, relates to medical instrument technical field, the treatment head includes the casing, drive subassembly, rotatory subassembly and transducer, the casing has the accommodation space, drive subassembly is installed in the accommodation space and is connected with the casing, rotatory subassembly is installed in the accommodation space, and the transducer is connected with the rotatory subassembly. The rotating assembly is connected to the moving end of the driving assembly, the rotating assembly is provided with a connecting piece, the connecting piece is provided with a rotating center, the transducer is connected to the connecting piece, the transducer is provided with a center shaft, and the center shaft of the transducer and the rotating center of the connecting piece are arranged in a non-coaxial mode; wherein the driving assembly drives the rotating assembly to drive the transducer to move in the first direction, and the rotating assembly drives the connecting piece to drive the transducer to eccentrically rotate. According to the technical scheme provided by the utility model, the problems of heavy structure and large occupied space of the existing treatment head adopting a double-screw scheme are solved.

The invention relates to the technical field of biomedicine, and particularly discloses application of MIDN protein in diagnosis and treatment of glioma. Glioblastoma (GBM) is the most common malignant glioma in the central nervous system and accounts for more than 50% of all glioma, and the existing treatment means face challenges of high drug resistance, poor prognosis and the like. Based on the association between protein degradation imbalance and tumor occurrence and development, the invention finds that MIDN can capture substrate protein through a Catch structural domain thereof and degrade carcinogenic substrate molecules (such as PPDPF) through a non-ubiquitin proteasome pathway, thereby inhibiting the malignant progression of glioma.